Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody

Published:2019-11-07 Issue:1 Volume:11 Page:15-18
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Fujita Kohei¹^ORCID,Yamamoto Yuki¹²,Kanai Osamu¹^ORCID,Okamura Misato¹,Hashimoto Masayuki³,Nakatani Koichi¹,Sawai Satoru³,Mio Tadashi¹

Affiliation:

1. Division of Respiratory Medicine, Center for Respiratory DiseasesNational Hospital Organization Kyoto Medical Center Kyoto Japan

2. Department of Drug Discovery for Lung Diseases, Graduate School of MedicineKyoto University Kyoto Japan

3. Division of Thoracic Surgery, Center for Respiratory DiseasesNational Hospital Organization Kyoto Medical Center Kyoto Japan

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13241

Reference13 articles.

1. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

2. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

4. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

5. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions;Cancer Letters;2024-11

2. Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial;The Lancet Respiratory Medicine;2024-09

3. Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study;Cancer Communications;2024-05-13

4. Retreatment with Immune Checkpoint Inhibitors in the New Scenario of Immunotherapy in Non-Small Cell Lung Cancer;Cancers;2024-04-26

5. Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse;Cancers;2024-03-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3